How to appeal a UnitedHealthcare rare disease — ert, substrate reduction, gene therapy denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for rare disease — ert, substrate reduction, gene therapy

Cited policy: UHC Commercial Medical Benefit Drug Policy: Enzyme Replacement Therapy (Optum Specialty Pharmacy mandatory)

Confirmed diagnosis by enzyme assay AND/OR genetic testing; specialist Rx; baseline organ assessment.

How UnitedHealthcare denies rare disease — ert, substrate reduction, gene therapy — and how to counter it

Where UnitedHealthcare pushes back: 1) Not dispensed through Optum Specialty / BriovaRx; 2) J-code billing inappropriate for site of service; 3) Insufficient documentation of enzyme deficiency.

Counter-arguments that hold up: Cite FDA orphan approval (rebuts experimental); attach enzyme assay report + genetic test result. For site-of-care: home infusion or hospital outpatient is medically necessary (peri-infusion monitoring, anaphylaxis risk per FDA black-box for Lumizyme/Aldurazyme/Naglazyme). Cite manufacturer-specific REMS or pivotal trial infusion protocol.

What UnitedHealthcare typically denies for rare disease — ert, substrate reduction, gene therapy

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For rare disease — ert, substrate reduction, gene therapy, expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the rare disease — ert, substrate reduction, gene therapy treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Pompe ERT
• Fabry ERT
• Galafold (Fabry SRT)
• Gaucher ERT
• Gaucher SRT
• MPS I ERT

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.